117833-18-8Relevant articles and documents
VEGF NEUTRALIZING PRODRUGS FOR THE TREATMENT OF OCULAR CONDITIONS
-
Page/Page column 146; 147, (2014/05/07)
The present invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable excipient(s) and a VEGF neutralizing prodrug, which comprises a VEGF neutralizing biologically active moiety, for use in a method for the treatment of one or more ocular conditions.
Using peptidic inhibitors to systematically probe the S1′ site of caspase-3 and caspase-7
Goode, David R.,Sharma, Anil K.,Hergenrother, Paul J.
, p. 3529 - 3532 (2007/10/03)
(Chemical Equation Presented) Fifteen ketone-containing peptides were designed, synthesized, and used to probe the effect of substitution at the P1′ position on caspase-3 and -7 inhibition. Even with the large bias of Ac-Asp-Glu-Val-Asp at the P4-P1 positions, certain peptides with cyclic functionality in the P1′ position show a dramatically reduced ability to inhibit these caspases. Additionally, trends toward isozyme selectivity were also uncovered for particular P1′ substituents. The data indicate that substitution in the P1′ position can drastically affect both caspase inhibition and selectivity.
N-acetylaspartylglutamic acid and its β-isomer
Piotrovskii, L. B.,Dumpis, M. A.,Poznyakova, L. N.,Aleksandrova, L. N.,Sepetov, N. F.
, p. 96 - 100 (2007/10/02)
The α-isomer is predominantly formed in the synthesis of N-acetylaspartylglutamic acid and its β-isomer upon cleavage of N-acetylaspartic acid anhydride by the diethyl ester of glutamic acid.